Cancer pain is an unpleasant sensory & emotional experience due to actual or potential tissue damage in patients with cancer.
Effective pain management in cancer patients with pain is an essential part of oncologic management due to increasing evidence of survival.
Pancreatic, head & neck cancer has a high prevalence of cancer pain.
During initial evaluation, follow-ups and new therapy initiation of patients with cancer, it is essential that they will be screened & evaluated for pain.

Patient Education

Patient & Family Education

  • Education on the use of analgesics & specific instructions about how to deal with uncontrolled pain are part of psychoeducational interventions
  • Education on issues related to cancer pain management is an essential element to effectively manage pain associated with cancer
  • Issues that the patient & the patient’s family/caregiver should addressed to are:
    • Understanding cancer pain
    • Understanding disease processes & their relation to pain
    • How to describe & document pain assessment appropriately
    • Understanding pain management
    • Awareness of the available analgesics
    • Dispelling fears regarding opioid analgesics
    • Accessing help & support
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers. 
29 Jan 2019
Carfilzomib in combination with dexamethasone (Kd) is effective and safe in patients with multiple myeloma (MM) relapsing on or after lenalidomide and those with lenalidomide-refractory disease, a combined analysis of carfilzomib trials has shown.
29 Jan 2019
A curative strategy for smoldering multiple myeloma (SMM) that involves induction therapy with carfilzomib, lenalidomide and dexamethasone (KRd) followed by high-dose melphalan and autologous stem cell transplantation (ASCT), KRd consolidation, and maintenance with lenalidomide and dexamethasone has demonstrated promising results in a phase II trial.
Pearl Toh, 07 Mar 2019
Sacituzumab govitecan, a novel investigational antibody-drug conjugate, showed clinical activity in patients with metastatic urothelial carcinoma (mUC) who had progressed following standard therapy, including treatment with checkpoint inhibitors, according to an early study presented at GUCS 2019.